MedTrace Logo

Expression of Molecular Markers in Circulating Tumor Cells of Metastatic Castration-Resistant Prostate Cancer

NCT03089099 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2017-05-01

No results posted yet for this study

Summary

As prostate cancer progresses into castration-resistant stage from initial hormone-sensitive status, the biological behavior of tumor cells that dissociated from primary lesions changed. Considered a "liquid biopsy," these circulating tumor cells (CTCs) can show how a patient's cancer responded to treatments. The purpose of this study is to determine whether sequentially analyzing the expression of molecular markers in high volume circulating tumor cells in metastatic castration-resistant prostate cancer patients can predict the therapeutic effects and outcomes of these patients.

Conditions

  • Prostate Cancer Metastatic

Interventions

OTHER

Blood drawing

Blood drawing

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Dai Bo, MD · Fudan University

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-24
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03089099 on ClinicalTrials.gov